Quantcast

Latest Protein kinase inhibitor Stories

2014-10-21 08:33:34

-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment

2014-10-16 12:28:14

Launch of Novel Immune Checkpoint Inhibitors Will Fuel Market Growth and Will Dramatically Enhance RCC Treatment Algorithm, According to Findings from Decision Resources Group BURLINGTON, Mass.,

2014-10-14 16:28:33

WOODCLIFF LAKE, N.J., Oct. 14, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.

2014-09-29 08:30:57

- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing

2014-07-16 12:28:07

For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.

2014-07-15 12:29:21

The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass.,

2014-07-01 04:21:47

-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.

2014-06-24 12:28:44

RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.

2014-05-31 08:20:45

Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.